DIA Biosimilars 2013

MEI Pharma

MEI Pharma acquires rights to Pathway drug candidate

Wednesday, September 11, 2013 01:29 PM

MEI Pharma, an oncology company focused on the clinical development of novel therapies for cancer, has acquired exclusive worldwide rights to the investigational drug candidate PWT143 from Pathway Therapeutics, a privately-held pharmaceutical company, for an undisclosed upfront payment with no future milestone or royalty obligations.

More... »

Cenduit: Now with Patient Reminders

MEI Pharma appoints Nick Glover to board of directors

Friday, June 14, 2013 01:35 PM

MEI Pharma, an oncology company focused on the clinical development of novel therapies for cancer, has appointed Nick Glover, Ph.D., to its board of directors, increasing the board to seven members, including six independent directors.

More... »

CRF Health – eCOA Forum

MEI Pharma to acquire S*BIO’s Pracinostat

Wednesday, August 8, 2012 09:46 AM

MEI Pharma, a San Diego-based oncology company, has entered into a definitive asset purchase agreement with S*BIO, a privately held biotech in Singapore, to acquire S*BIO's exclusive worldwide rights to Pracinostat, an investigational, potential best-in-class, oral histone deacetylase (HDAC) inhibitor.

More... »

Marshall Edwards changes name to MEI Pharma

Tuesday, July 3, 2012 11:31 AM

Marshall Edwards, a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, had decided to change its name to MEI Pharma, and its common stock will begin trading under the new ticker symbol MEIP.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs